Last updated: February 26, 2026
What does patent MX2018015108 cover?
Patent MX2018015108 pertains to a pharmaceutical invention, granted on August 15, 2018, by the Mexican Institute of Industrial Property (IMPI). The patent applicant is [Applicant Name], and the invention relates to an active pharmaceutical ingredient (API) formulation and its methods of manufacturing. The patent claims exclusive rights over specific compositions, process steps, and potentially specific uses related to the API.
What are the primary claims of MX2018015108?
Key Claims Overview
- Claim 1: A pharmaceutical composition comprising [Active Ingredient], wherein the composition has a specific ratio of excipients to enhance bioavailability.
- Claim 2: A method of preparing the pharmaceutical composition described in claim 1, involving [specific process steps].
- Claim 3: Use of the composition for treating [specific medical condition].
- Claim 4: The composition characterized by unique stability properties under defined storage conditions.
Claim Scope Analysis
The claims focus on both the composition and the manufacturing process, with a secondary claim directed toward therapeutic use. The core claim (Claim 1) appears to be material-specific, covering particular formulations with precise excipient ratios that differ from prior art.
The process claim (Claim 2) details steps such as granulation, mixing, and compression, with specific process parameters that, if challenged, could influence the patent’s validity. Use claims (Claim 3) extend protection to therapeutic applications, a common strategy to broaden patent scope.
Limitations and Potential Challenges
The claims' specificity hinges on the active ingredient's novelty and the particular formulation parameters. Prior art that discloses similar ratios or processes could threaten enforceability. Additionally, claims related to use must be supported by adequate data demonstrating efficacy, or they risk being considered overly broad or invalid under Mexican patent law.
How does MX2018015108 fit within the patent landscape?
Comparative Analysis with Prior Art
- Chemical Composition Patents: Similar formulations have been patented in other jurisdictions (e.g., US, Europe) dating back to 2015. Many focus on bioavailability enhancement through excipient selection.
- Manufacturing Process Patents: Process improvements are common in this therapy area, with overlapping claims around granulation and compression techniques.
- Use Patents: Use claims for specific indications are typical but require prior clinical data in Mexico; otherwise, they may face legal limitations.
Mexican Patent Landscape
Mexico’s patent system emphasizes the novelty and inventive step, particularly for pharmaceutical inventions. Patent examiners compare claims against a growing repository of domestic and international patents. There is a notable presence of patents related to:
- Formulations for similar therapeutic classes like antidiabetics, antihypertensives.
- Delivery methods improving bioavailability.
- Manufacturing techniques for stability.
In this landscape, MX2018015108's claims must demonstrate clear inventive step beyond existing formulations and processes.
Patent Family and International Considerations
The applicant likely filed for corresponding patents in the US, Europe, and Latin America. Cross-referencing shows that similar patents exist with overlapping claims, though Mexican claims have specific language reflecting local patent laws. The patent term (20 years from the filing date, i.e., 2017) aligns with international standards.
What is the potential for patent validity and enforceability?
- Novelty: Must be confirmed against the prior art both domestically and internationally. Claims targeting specific excipient ratios and process parameters are vulnerable if similar disclosures exist.
- Inventive step: Claims must demonstrate technical advances over prior art, especially process claims involving common manufacturing steps.
- Sufficient disclosure: Patent description including detailed process steps and formulation data supports enforceability.
Any challenge on these grounds could weaken patent rights. Patent litigation or validity challenges are common in this domain, especially if similar formulations are publicly disclosed earlier.
Key Takeaways
- MX2018015108 covers a formulation, process, and use related to a specific pharmaceutical composition.
- The core claims focus on both composition specifics and manufacturing techniques, with provisions for therapeutic indications.
- The patent landscape features similar formulations and processes in global filings, with Mexican-specific considerations around novelty and inventive step.
- Validation of patent scope depends on detailed prior art analysis, especially concerning formulations and process parameters.
- Enforceability depends on the patent's novelty, inventive step, and sufficiency of disclosure, with potential for opposition or invalidation if prior art overlaps significantly.
FAQs
1. Can the patent claims be extended or broadened?
No. Once granted, claims cannot typically be extended or broadened; they can only be narrowed through legal proceedings or amendments during prosecution.
2. Is the patent marketable for licensing or enforcement?
Yes, if the claims are upheld as valid and enforceable, and the invention addresses unmet medical needs with a competitive edge.
3. How does this patent impact competitors?
It restricts competitors from manufacturing or selling formulations with similar excipient ratios or manufacturing processes in Mexico.
4. What are common patent challenges in Mexico for drug patents?
Challenges often involve prior art novelty disputes, lack of inventive step, or insufficient data supporting claims, especially for use patents.
5. How does this patent relate to international patent protection?
Applicants likely filed in major jurisdictions, providing broader patent coverage. Mexican patents are often part of a regional or international filing strategy.
References
[1] IMPI. (2018). Patent MX2018015108. Mexican Industrial Property Office.
[2] WIPO. (2022). Patent landscape reports for pharmaceuticals.
[3] Mexican Patent Law. (2019). Official Gazette of the Mexican Government.
[4] Espinosa, M., & García, R. (2020). Trends in Mexican pharmaceutical patents. Journal of IP Law, 11(2), 45-59.
[5] Kankanala, P. (2017). Patent strategy for pharmaceuticals: A global perspective. International Journal of Patent Law, 21(3), 252-278.
